Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

A J&J veteran highlights listening to address overlooked maternal-fetal needs

By Brian Buntz | December 27, 2023

Mid-section portrait of unrecognizable woman during last months of pregnancy holding her big belly gently standing against wall in blue room

[pressmaster/Adobe Stock]

With nearly 20 years of experience at Johnson & Johnson, Cynthia Accuosti Jones now spearheads the company’s pioneering maternal-fetal medicine group tackling unmet needs in high-risk pregnancies. As vice president of global commercial strategy for autoantibody and maternal fetal health, she spotlights listening as the driver for patient impact. “You can’t have empathy if you don’t listen to people and it’s incredible how much people just need to be listened to,” Jones emphasized, underscoring the importance of addressing the often-neglected area of maternal health.

Jones’ longtime interest in healthcare, rooted in her desire to help people, initially led her to consider nursing. However, she ultimately chose to study finance and international business at Georgetown, a decision influenced by her childhood experience in tracking her father’s stocks. This early exposure to the financial world piqued her interest in financial markets and data analysis

After graduating, Jones faced a decision common to many graduates: whether to pursue a conventional path in finance, potentially on Wall Street or in the financial services industry.

While such a path was clear, Jones’ call to serve a greater purpose, combined with a childhood in the pharma cluster of New Jersey, led to her accepting a role as a financial analyst in sales and marketing at Johnson & Johnson. 

Asking “why” to transform patient outcomes

Cynthia Accuosti

Cynthia Accuosti

While at J&J, she became part of the company’s Finance Leadership Development Program (FLDP), which provided a broad overview of the company’s operations. Though initially on a finance track, Jones gravitated toward commercial operations seeking to link decisions to patient outcomes. “I was always trying to understand the ‘why’ behind the decisions that we were making,” she said. That also included examining which real-world factors shaped strategic deliberations around delivery of care and investment.

Over the years, Jones would go on to hold a number of roles at the company, including positions in the oncology sector and managed markets. Her roles ranged from leading national account management across specialty and non-specialty businesses to overseeing lifecycle planning strategies in oncology marketing.

Ultimately, Jones’ curiosity and patient focus attracted her to lead commercial strategy for a pioneering business unit addressing overlooked needs in maternal health. This includes efforts related to nipocalimab, an investigational drug targeting severe Hemolytic Disease of the Fetus and Newborn (HDFN), a rare condition that can cause life-threatening anemia in fetuses. “We’re really proud to be the only manufacturer that’s actively pursuing non-invasive treatments in these maternal fetal diseases like hemolytic disease of the fetus and newborn,” Jones shared.  “We are treating the mom as well as the baby.”

The focus is noteworthy given the traditional lack of research focus on maternal healthcare. “Pregnant women have really not been studied in many trials at all, let alone studying diseases that develop while pregnant.”

Collaborative leadership drives J&J maternal fetal efforts

In her role, Jones works closely with Dr. Katie Abouzahr, J&J’s vice president of autoantibody portfolio and maternal fetal disease area leader, on aligning commercial and R&D strategies. “Katie and I come to work every day to solve the same problem,” Jones said. “We have to figure out how to develop these medicines and get them to patients. There is a singular strategy. And we have to motivate and help create vision and guide a number of different functions, all of which have their own incredible expertise.”

Jones acknowledges the role of prior mentors in shaping her growth-focused leadership style, recalling one leader who advised, “There’s no growth in the comfort zone, there’s no comfort in the growth zone.” As a parent, this sentiment resonated deeply. She reflected, “If we don’t push ourselves and our teams to constantly innovate, how can we expect to deliver?” This drive to help individuals achieve more manifests in her team leadership. Whether guiding colleagues or her family, she aims “to be the best version of myself” while enabling others’ success. 

Paying it forward: Mentorship and leadership philosophy

Jones pays forward the mentorship she received to develop future leaders. She devotes substantial time to guiding younger colleagues, noting the reciprocal value of these relationships. “I get more out of the conversations sometimes than I think they do,” she said.

This ethos of empowering potential manifests across Jones’ leadership. By asking “What problem are we solving?” she aligns teams towards strategic goals. With empathy fueled by curiosity, she creates environments where people feel heard and ideas thrive. Ultimately, it comes back to listening, which Jones spotlights as foundational.

Whether illuminating overlooked needs in maternal health or cultivating talent within J&J’, Jones has a substantial amount of experience to draw on to drive impact. But she never stops listening. Because it is through hearing each voice that the next innovation may emerge. And with it, the possibility to further life’s potential — both at J&J and beyond the company’s walls.


Filed Under: Obstetrics & gynecology, Women in Pharma and Biotech
Tagged With: biopharma innovation, fetal medicine, healthcare leadership, high-risk pregnancy, Johnson & Johnson, Maternal health, medical research, nipocalimab, pharmaceutical development
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Endometriosis: An immune disease
Biomimetic digital twin ecosystem process tailored for the analysis.
Study combines biomimetic AI, digital twins and multiomics to unveil potential genetic drivers of endometriosis
positive pregnancy test in the hands of a girl close-up
The rise of ‘Ozempic babies’ and the uncharted territory of semaglutide in pregnancy
Johnson & Johnson
How a J&J exec found her calling in autoantibody drug development
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE